Serina Therapeutics, Inc.
SER
$5.70
-$0.15-2.56%
AMEX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -100.45% | -51.72% | 628.57% | -83.33% | 5,259.38% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.45% | -51.72% | 628.57% | -83.33% | 5,259.38% |
| Cost of Revenue | 160.75% | 300.50% | 232.78% | 177.19% | 267.95% |
| Gross Profit | -209.13% | -318.29% | -226.91% | -198.37% | 1,254.05% |
| SG&A Expenses | 398.24% | 227.45% | 391.12% | 105.73% | -33.00% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 225.50% | 256.97% | 311.45% | 134.48% | 65.36% |
| Operating Income | -321.36% | -263.09% | -309.10% | -141.27% | 364.18% |
| Income Before Tax | -361.85% | -21.06% | 540.72% | -1,005.61% | 275.64% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -361.85% | -21.06% | 540.72% | -1,005.61% | 275.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -360.70% | -19.52% | 544.06% | -1,005.61% | 275.64% |
| EBIT | -321.36% | -263.09% | -309.10% | -141.27% | 364.18% |
| EBITDA | -317.61% | -273.03% | -310.45% | -141.94% | 371.39% |
| EPS Basic | -235.74% | -80.09% | 64.30% | -803.40% | 256.22% |
| Normalized Basic EPS | -136.96% | 140.93% | 274.74% | -609.02% | 408.61% |
| EPS Diluted | -293.31% | -43.48% | 356.99% | -2,790.85% | 155.54% |
| Normalized Diluted EPS | -203.60% | 216.76% | 601.09% | -2,703.91% | 210.09% |
| Average Basic Shares Outstanding | 668.49% | 304.16% | 291.99% | 28.75% | 12.42% |
| Average Diluted Shares Outstanding | 174.20% | 41.76% | 36.63% | -67.44% | 215.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |